Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NIO Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while NIO Inc. trades at $4.51 (market cap $11.39B). The key difference: NIO Inc. is far larger — about 2.2× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | NIO | |
|---|---|---|
Market Cap | $5.07B | $11.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.45 | $7.89 |
52-Week Low | $20.06 | $4.44 |
Enterprise Value | $4.19B | $10.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
NIO trades at $4.50, down 2.6% with bearish technical signals despite recent earnings beats. The EV maker shows improving revenue growth to $87.49B in 2025 but continues posting significant losses (-$15.57B net income). Analyst sentiment remains positive with 54% buy ratings, though institutional selling pressure and competitive headwinds weigh on the stock. Recent delivery growth contrasts with negative cash flow trends and high debt levels.
NIO presents a high-risk opportunity with improving fundamentals but persistent profitability challenges. The stock's current valuation at 0.72 P/S offers potential upside if execution improves, though investors face substantial risk from cash burn, intense competition, and macroeconomic pressures in the Chinese EV market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
